What is the recommended treatment for a patient with a 1 cm solitary pulmonary nodule in the upper right lung consistent with early‑stage non‑small cell lung cancer?

Treatment of 1 cm Solitary Pulmonary Nodule in Upper Right Lung Consistent with Early-Stage NSCLC

For a medically fit patient with a 1 cm peripheral solitary pulmonary nodule in the upper right lung consistent with early-stage NSCLC, surgical resection via minimally invasive approach is the definitive treatment, with segmentectomy or wedge resection being equivalent to lobectomy for tumors ≤2 cm. 1

Surgical Approach and Extent of Resection

Primary Treatment Strategy

• Surgical resection with curative intent remains the gold standard for early-stage resectable NSCLC in patients who can tolerate the operation 2
• For this 1 cm peripheral nodule, you have equivalent surgical options: lobectomy, segmentectomy, or sublobar wedge resection 1

Minimally Invasive Surgery Preference

• Video-assisted thoracoscopic surgery (VATS) is preferred over thoracotomy for stage I NSCLC, as meta-analysis demonstrates an association between minimally invasive surgery and better overall survival outcomes 1
• VATS segmentectomy results in less intraoperative blood loss and shorter hospital stays compared to lobectomy, with similar 1-year survival rates 3

Critical Technical Requirements

If performing segmentectomy or wedge resection, the surgical margin must be either >2 cm OR have a margin-to-tumor size ratio >1, confirmed at the time of resection 1

• For a 1 cm tumor, this means achieving at least a 1 cm margin (ratio of 1:1) or ideally >2 cm absolute margin
• Systematic intraoperative mediastinal and hilar lymph node sampling or dissection is mandatory during operations for stage I and II NSCLC to ensure accurate staging and confidence in the appropriateness of limited resection 1

Pre-Surgical Evaluation Requirements

Confirm Diagnosis and Staging

• The nodule should be evaluated with chest CT imaging to characterize size, location, and solid versus ground-glass components 4
• For solid nodules ≥8 mm (which includes this 1 cm nodule), management is based on estimated probability of malignancy, patient comorbidities, and preferences 4
• PET-CT imaging is valuable for nodules with intermediate to high probability of malignancy to assess for occult metastatic disease 5

Risk Assessment

• Patients must be medically fit and at average or low operative risk for surgical resection 1
• Those with significant comorbidities or high surgical risk require individualized assessment, potentially considering stereotactic body radiotherapy (SBRT) as an alternative 1

Adjuvant Therapy Considerations

Post-Surgical Treatment

• For resected stage IB tumors ≥3 cm with EGFR mutations, adjuvant targeted therapy (osimertinib) improves overall survival 1
• Since this nodule is only 1 cm, it would be classified as stage IA, where adjuvant systemic therapy is generally not indicated unless upstaged by lymph node involvement found during surgery 2, 1
• If surgical pathology reveals stage II disease or lymph node involvement, adjuvant chemotherapy plus checkpoint inhibitors improves overall survival 1

Alternative for Non-Surgical Candidates

Stereotactic body radiotherapy (SBRT) is the preferred approach for patients with stage I NSCLC who are not appropriate candidates for surgical resection due to medical comorbidities or patient refusal of surgery 1

Common Pitfalls to Avoid

• Do not perform limited resection without adequate surgical margins (>2 cm or margin:tumor ratio >1) 1
• Do not skip systematic lymph node sampling/dissection during surgery, as this is essential for accurate staging and determining need for adjuvant therapy 1
• Do not assume all 1 cm nodules are benign - nodules 6-8 mm have 1-2% malignancy probability, but this increases substantially for nodules ≥8 mm 4
• Ensure molecular testing is performed on resected specimens to identify actionable mutations that may benefit from adjuvant targeted therapy if tumor is upstaged 2